Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation.
暂无分享,去创建一个
H. Deeg | P. Hari | M. Sorror | M. Maris | R. Storb | B. Sandmaier | D. Maloney | B. Storer | D. Niederwieser | P. Mcsweeney | M. Mielcarek | M. Pulsipher | R. Maziarz | Paul J. Martin | A. Langston | W. Bethge | B. Bruno | H. Deeg | F. Petersen | A. Yeager | G. Georges | M. Flowers | K. Hübel | L. Vindeløv | Georg-Nikolaus Franke | K. Blume | A. Woolfrey | T. Chauncey | B. Gyurkocza | G. Laport | F. Sahebi | E. Agura | M. Flowers | M. Mielcarek | David G. Maloney | P. Martin | Richard T. Maziarz | Ann E. Woolfrey | H. Joachim Deeg | Barry E. Storer | Edward D. Agura | Amelia A. Langston | Ginna G. Laport | G. Franke | Paul J. Martin | Michael B. Maris | Mary E.D. Flowers | H. Deeg | Boglarka Gyurkocza | Mohamed L. Sorror | Thomas R. Chauncey | Finn Petersen | Peter A. McSweeney | Michael B. Maris | Andrew M. Yeager | P. Martin | Andrew M. Yeager | F. Petersen | Amelia A. Langston
[1] H. Greinix,et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease , 2015 .
[2] Daniel Wolff,et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[3] R. Gale,et al. SIMILAR OUTCOMES USING MYELOABLATIVE VERSUS REDUCED INTENSITY ALLOGENEIC TRANSPLANT PREPARATIVE REGIMENS FOR AML OR MDS , 2011, Bone Marrow Transplantation.
[4] E. Estey,et al. A Phase II Open-Label, Ac220 Monotherapy Efficacy Study In Patients with Refractory/Relapsed Flt3-Itd Positive Acute Myeloid Leukemia: Updated Interim Results , 2011 .
[5] T. Brümmendorf,et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. , 2011, Blood.
[6] M. Maris,et al. Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia , 2011, Haematologica.
[7] J. Ritz,et al. Use of matched unrelated donors compared with matched related donors is associated with lower relapse and superior progression-free survival after reduced-intensity conditioning hematopoietic stem cell transplantation. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[8] R. Storb,et al. Influence of immunosuppressive treatment on risk of recurrent malignancy after allogeneic hematopoietic cell transplantation. , 2011, Blood.
[9] R. Storb,et al. A retrospective comparison of tacrolimus versus cyclosporine with methotrexate for immunosuppression after allogeneic hematopoietic cell transplantation with mobilized blood cells. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[10] D. Kaufman,et al. Reduced-intensity conditioning followed by related allografts in hematologic malignancies: long-term outcomes most successful in indolent and aggressive non-Hodgkin lymphomas. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[11] R. Storb,et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. , 2011, Blood.
[12] K. Peggs,et al. Donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation , 2011, Expert opinion on biological therapy.
[13] R. Bouabdallah,et al. Reduced-intensity conditioning with Fludarabin, oral Busulfan, and thymoglobulin allows long-term disease control and low transplant-related mortality in patients with hematological malignancies. , 2010, Experimental hematology.
[14] N. Schmitz,et al. CNS Disease In Younger Patients ( , 2010 .
[15] Scott E. Smith,et al. Results of a Pivotal Phase 2 Study of Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma , 2010 .
[16] R. Porcher,et al. The graft-versus-leukemia effect is mainly restricted to NIH-defined chronic graft-versus-host disease after reduced intensity conditioning before allogeneic stem cell transplantation , 2010, Leukemia.
[17] R. Storb,et al. Impact of recipient statin treatment on graft-versus-host disease after allogeneic hematopoietic cell transplantation. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[18] W. Shannon,et al. In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia. , 2010, Blood.
[19] S. Heimfeld,et al. Donor statin treatment protects against severe acute graft-versus-host disease after related allogeneic hematopoietic cell transplantation. , 2009, Blood.
[20] J. Klein,et al. Donor, recipient, and transplant characteristics as risk factors after unrelated donor PBSC transplantation: beneficial effects of higher CD34+ cell dose. , 2009, Blood.
[21] R. Storb,et al. What is the role for donor natural killer cells after nonmyeloablative conditioning? , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[22] A. Barrett,et al. The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. , 2009, Blood.
[23] J. Bourhis,et al. Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire. , 2008, Experimental hematology.
[24] M. Maris,et al. Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. , 2007, Blood.
[25] B. Sandmaier,et al. Reduced-intensity conditioning for unrelated donor progenitor cell transplantation: long-term follow-up of the first 285 reported to the national marrow donor program. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[26] J. Klein,et al. Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT. , 2007, Blood.
[27] M. Labopin,et al. Reduced-intensity conditioning regimen using low-dose total body irradiation before allogeneic transplant for hematologic malignancies: Experience from the European Group for Blood and Marrow Transplantation. , 2007, International journal of radiation oncology, biology, physics.
[28] M. Horowitz,et al. Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. , 2005, Blood.
[29] M. Sorror,et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] M. Sorror,et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. , 2005, Blood.
[31] M. Turner,et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[32] R. Storb,et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissio , 2003, Blood.
[33] Katia Perruccio,et al. Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants , 2002, Science.
[34] J. Radich,et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. , 2001, Blood.
[35] A. Tosti,et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. , 1999, Blood.
[36] J Crowley,et al. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. , 1999, Statistics in medicine.
[37] A. Rimm,et al. Graft-versus-leukemia reactions after bone marrow transplantation. , 1990, Blood.
[38] W. Wilmanns,et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. , 1990, Blood.
[39] W. Gregory,et al. Bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: importance of a graft‐versus‐leukaemia effect , 1988, British journal of haematology.
[40] R. Storb,et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. , 1979, The New England journal of medicine.
[41] M. Tubiana,et al. SUCCESSFUL ALLOGENIC BONE MARROW TRANSPLANTATION IN MAN: CHIMERISM, INDUCED SPECIFIC TOLERANCE AND POSSIBLE ANTI-LEUKEMIC EFFECTS. , 1965, Blood.
[42] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[43] J. Loutit,et al. Treatment of Murine Leukaemia with X Rays and Homologous Bone Marrow , 1956, British medical journal.